S358120677.onlinehome.us

EUTHYMICS BIOSCIENCE, INC. NAMES BIOTECH EXECUTIVE TIMOTHY J. BARBERICH
TO BOARD OF DIRECTORS
-- Former Sepracor Founder and CEO Brings a History of Experience and Success in Drug
Development and Commercialization --

Cambridge, MA – November 4, 2010 - Euthymics Bioscience, Inc., a clinical-stage company developing
next-generation antidepressants, today announced that Timothy J. Barberich, the founder and former
CEO of Sepracor, Inc., has joined the company’s Board of Directors as an independent board member,
bringing the total number of board members to five. Mr. Barberich brings to Euthymics a long history of
hands-on experience as a successful biotechnology industry executive.
Euthymics’ lead product candidate EB-1010 is a novel, triple reuptake inhibitor antidepressant intended
for use by the estimated two-thirds of major depression patients who do not respond adequately to the
current medications available within the $20 billion worldwide antidepressant market. The addition of Mr.
Barberich to the Euthymics Board supports critical upcoming milestones—the company is preparing to
present Phase II major depression data in a peer-reviewed forum, and to initiate a major Phase II/III
clinical trial, also in major depression.
“Timothy Barberich developed the strategy and recruited the team that led to the development and
success of Sepracor. His knowledge, particularly in the field of central nervous system disorders, will be
invaluable to Euthymics’ own growth and development,” said Anthony A. McKinney, President, CEO and
Co-Founder of Euthymics. “As we work to develop a world-class Board of Directors and adhere to the
highest standards of good governance practices, we are pleased to have Tim join us as a key advisor.”
Mr. Barberich founded Sepracor, a fully integrated research pharmaceutical company, in 1984 and served
as CEO and Chairman. Under his leadership at Sepracor, revenues grew to more than a billion dollars as
the company partnered and commercialized a number of successful products, including Allegra®,
Clarinex® and Lunesta®. In 2009 Sepracor was acquired by Dainippon Sumitomo for $2.6 billion to form
one of the largest Japanese-based global pharmaceutical companies. Prior to Sepracor, Mr. Barberich
held a series of management positions at Millipore as the company grew to over a billion dollars in
revenue serving the life sciences industry.
About Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation
treatments for central nervous system disorders. The company’s lead product candidate, EB-1010 for
depression, is a triple reuptake inhibitor that acts on serotonin, norepinephrine and dopamine in a specific
unbalanced ratio and is given as monotherapy (a single capsule). EB-1010 has demonstrated proof-of-
concept efficacy as treatment for major depression without causing weight gain or loss of sexual function,
which often lead to poor adherence to standard antidepressants.
Euthymics also plans to develop a second triple reuptake inhibitor, EB-1020, which is in the late research
stage, for adult ADHD and neuropathic pain.
Euthymics is a privately held company with headquarters in Cambridge, Massachusetts. Additional
information can be found on the company’s website at
Contacts:
Euthymics Bioscience, Inc.
Anthony A. McKinney, 617-758-0300
Media:
BioCom Partners
Stephen Gendel, Jennifer Anderson, 212-918-4650

Source: http://s358120677.onlinehome.us/wp-content/uploads/2010/11/Euthymicsappointment_110410.pdf